Metriopharm
  • en
  • de
MetrioPharm AG
  • Home
  • About us
    • Our Company
    • Management and Board
    • Scientific Advisory Board
    • Career
  • Technology
    • MetrioPharm Platform
    • Mechanism of Action
    • Safety
    • Scientific Publications
  • Pipeline
    • Indications
    • Patent Protection
  • Investors
    • IR-News
    • Financial Report and Statutes
    • Annual General Meeting
  • Press
    • Press Releases
    • Corporate Calendar
  • Contact
    • Contact
    • Privacy policy
    • Imprint
  • en
  • de
  1. Home
  2. Investors
  3. Financial Report and Statutes

Financial Report and Statutes

 

MetrioPharm AG Annual Report 2024

MetrioPharm AG Annual Report 2024


Statutes

Statutes of MetrioPharm AG (November 2023, German only)

 

Investor Relations

Investor-Newsletter QIV 2025 - 2025-Dec-22

Key progress in dose selection and safety, EMA Orphan Drug Designation, How MP1032 works in the body, Manufacturing and independence, Acknowledgements

» more

Please find our corporate slide-deck as download here:
» MetrioPharm corporate slide-deck

 

The iMPact project is one of six initiatives selected by the European Commission to work on drug candidates for the treatment of SARS-CoV-2. The project includes the conduct of a Phase II clinical trial with MetrioPharm's lead compound MP1032 against COVID-19.
» Find out more in the iMPact project film

PR Subscription

Subscribe to our press releases with the
MetrioPharm PR newsletter

Navigation

  • Home
  • About us
  • Technology
  • Pipeline
  • Investors
  • Press
  • Contact

Social

        

Press Releases

Subscribe to our press releases with the
MetrioPharm PR newsletter

Switzerland (HQ)

MetrioPharm AG

Europaallee 41
8004 Zurich

Germany (R&D)

MetrioPharm Deutschland GmbH

Franklinstrasse 28/29
10587 Berlin
  • © 2026 MetrioPharm AG
  • Imprint
  • Privacy policy (We don’t collect cookies)
  • Sitemap